These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38469732)

  • 1. Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial.
    El-Komy MHM; Sayed KS; Gawish G; Elaguizy MM; Azzazi Y
    Clin Exp Dermatol; 2024 Aug; 49(9):1029-1035. PubMed ID: 38469732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine weekly pulse versus methotrexate for the treatment of chronic plaque psoriasis: A randomized controlled trial.
    Verma KK; Kumar P; Bhari N; Gupta S; Kalaivani M
    Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):509-514. PubMed ID: 33871211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
    Singh SK; Singnarpi SR
    Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
    Erduran F; Emre S; Hayran Y; Adışen E; Polat AK; Üstüner P; Öztürkcan S; Öztürk P; Ermertcan AT; Selçuk LB; Aksu EK; Akbaş A; Kalkan G; Demirseren D; Kartal SP; Topkarcı Z; Kılıç A; Yaldız M; Aytekin S; Hızlı P; Gharehdaghi S; Borlu M; Işık L; Botsalı BR; Solak EÖ; Albayrak H; Gönülal M; Balcı DD; Polat M; Daye M; Ataseven A; Yıldız S; Özer İ; Zorlu Ö; Doğan S; Erdemir VA; Dikicier BS
    Arch Dermatol Res; 2024 May; 316(6):278. PubMed ID: 38796658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF; Chen JS; Gu J; Xu JH; Jin HZ; Pang XW; Wang G; Yu C; Song ZQ; Guo ZP; Li W; Lai W; Cui PG; Chen M; Fang H; Lyu CZ; Li YZ; Sun Q; Xie HF; Liu XM; Gao XH; Shi YL; Zhao NQ; Zhang W; Zheng M
    Arch Dermatol Res; 2020 Aug; 312(6):437-445. PubMed ID: 31873772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
    Gottlieb AB; Langley RG; Strober BE; Papp KA; Klekotka P; Creamer K; Thompson EH; Hooper M; Kricorian G
    Br J Dermatol; 2012 Sep; 167(3):649-57. PubMed ID: 22533447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
    Tournier A; Khemis A; Maccari F; Reguiai Z; Bégon E; Fougerousse AC; Amy de la Breteque M; Beneton N; Parier J; Boyé T; Avenel-Audran M; Girard C; Pallure V; Perrot JL; Bastien M; Mahé E; Beauchet A;
    Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M; Bonesrønning JH
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral fumaric acid esters for psoriasis.
    Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M; Chams-Davatchi C; Hemami MR; Fateh S
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
    Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
    Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial.
    Gerbens LAA; Hamann SAS; Brouwer MWD; Roekevisch E; Leeflang MMG; Spuls PI
    Br J Dermatol; 2018 Jun; 178(6):1288-1296. PubMed ID: 29237228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis.
    Attwa EM; Elkot RA; Abdelshafey AS; Hafez AR
    Dermatol Ther; 2019 Sep; 32(5):e13051. PubMed ID: 31381231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.